Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 1;60(1):15-23.
doi: 10.2169/internalmedicine.4214-19. Epub 2020 Feb 1.

Molecular Pathogenesis and Treatment of Myelodysplastic Syndromes

Hideaki Nakajima  1
Affiliations

Molecular Pathogenesis and Treatment of Myelodysplastic Syndromes

Hideaki Nakajima. Intern Med. .

Abstract

Myelodysplastic syndromes (MDS) are clonal hematological disorders arising from hematopoietic stem cells that have accumulated various genetic abnormalities. MDS are heterogeneous in nature but uniformly characterized by chronic and progressive cytopenia from ineffective hematopoiesis, dysplasia in single or multiple lineages, and transformation to acute leukemia in a subset of patients. The genomic landscape revealed by next-generation sequencing has provided a comprehensive picture of the molecular pathways involved in MDS pathogenesis. Recurrent mutational targets in MDS are the genes involved in RNA splicing, DNA methylation, histone modification, transcription, signal transduction, cohesin complex and DNA repair. Sequential acquisition of mutations in these sets of genes serves as a driver for the initiation, clonal evolution and progression of MDS. Based on these findings, novel agents targeting driver mutations of MDS are currently under development and expected to improve the clinical outcome of MDS in the coming decades.

Keywords: MDS; epigenome; genome; molecular pathogenesis; myelodysplastic syndromes; treatment.

PubMed Disclaimer

Conflict of interest statement

Author's disclosure of potential Conflicts of Interest (COI).

Hideaki Nakajima: Research funding, Daiichi-Sankyo.

Figures

Figure 1.
Figure 1.
Genetic abnormalities in MDS. Recurrently mutated genes in MDS (shown in red characters) and their roles in physiological pathways are shown. MDS: myelodysplastic syndromes
Figure 2.
Figure 2.
Molecular mechanism underlying the clonal evolution from lower-risk MDS to AML. Type 2 mutations are commonly seen during the evolution from lower-risk MDS to higher-risk MDS. Type 1 mutations are mainly involved in the transformation from higher-risk MDS to AML. MDS: myelodysplastic syndromes, AML: acute myeloid leukemia
See this image and copyright information in PMC

References

    1. Ogawa S. Genetics of MDS. Blood 133: 1049-1059, 2019. - PMC - PubMed
    1. Haase D. Cytogenetic features in myelodysplastic syndromes. Ann Hematol 87: 515-526, 2008. - PMC - PubMed
    1. Haase D, Germing U, Schanz J, et al. . New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 110: 4385-4395, 2007. - PubMed
    1. Boultwood J, Pellagatti A, McKenzie AN, Wainscoat JS. Advances in the 5q- syndrome. Blood 116: 5803-5811, 2010. - PubMed
    1. Bernasconi P, Klersy C, Boni M, et al. . Incidence and prognostic significance of karyotype abnormalities in de novo primary myelodysplastic syndromes: a study on 331 patients from a single institution. Leukemia 19: 1424-1431, 2005. - PubMed